Sign in Subscribe
Cancer research

10-Year Oncological Outcomes of EBRT vs HIFU for Stage II Prostate Cancer: A Multicenter Study

Strategic Insights

— 1 min read

Researchers at Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, Taiwan, have published a study evaluating the oncological outcomes of external beam radiation therapy (EBRT) versus high-intensity focused ultrasound (HIFU) in patients with stage II prostate cancer. The study retrospectively reviewed patients from the Chang Gung Research Database spanning 2005 to 2022, with a total of 176 EBRT and 244 HIFU procedures identified. The research found that HIFU demonstrated non-inferior overall survival and cancer-specific survival compared to EBRT in patients with stage II prostate cancer, particularly in the stage IIa subgroup.

Key Takeaways:

  • The study used inverse probability of treatment weighting (IPTW) method to achieve baseline equivalence and assess oncology outcomes including overall survival (OS) and cancer-specific survival (CSS).
  • EBRT group had higher overall mortality (9.2% compared to 16.7% after IPTW) and cancer-specific mortality (5.4% compared to 9.2% after IPTW) after IPTW adjustment.
  • An overall survival benefit is observed in the HIFU group for all stage II prostate cancer cases, with a particularly significant advantage in the stage IIa subgroup after IPTW adjustment (p = 0.032).
  • EBRT was associated with significantly worse OS compared to HIFU across univariate, multivariate, and IPTW-adjusted Cox regression models, with hazard ratios ranging from 2.03 to 2.63 (all p < 0.05).
  • The study concluded that further randomized prospective studies are needed to evaluate the oncological outcomes of different prostate cancer treatment modalities.

Statistics:

  • 176 EBRT and 244 HIFU procedures were identified in the study.
  • EBRT group had higher overall mortality (9.2% compared to 16.7% after IPTW) and cancer-specific mortality (5.4% compared to 9.2% after IPTW) after IPTW adjustment.
  • The hazard ratio for OS in the Cox regression model was 2.03 (p < 0.05) for the stage IIa subgroup.
  • The study used the IPTW analysis to adjust for potential confounding variables.

Sources:

  • 10-year oncological outcomes of EBRT versus HIFU for stage II prostate cancer: a multicenter Chang Gung research database (CGRD) study with inverse-probability-of-treatment weighting (IPTW) analysis. International Urology and Nephrology, 2025.
  • Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands.

Read more